论文部分内容阅读
目的观察神经节苷脂(Gg)注射液对重症颅脑损伤患者血清神经元特异性烯醇化酶(NSE)及S100B蛋白浓度的影响。方法 68例急性颅脑损伤患者随机分为对照组34例和试验组34例。对照组给予复方甘露醇注射液,每次200m L,每天2次,静脉滴注;脑复康1.2 g,每天3次,口服;试验组在对照组的基础上静脉滴注单唾液酸四己糖神经节苷脂100 mg,每天1次,2组疗程均为2个月。分别在患者住院后的第8,24,48,72,120 h采集空腹外周静脉血,用酶联免疫吸附法对2组患者血清NES和S100B蛋白进行检测,同时评价2组患者的临床疗效,观察2组的药物不良反应发生情况。结果治疗后120 h,试验组和对照组的血清NSE分别为(13.21±2.78),(18.52±3.45)ng·mL~(-1),S100B分别为(2.08±0.85),(3.76±2.14)ng·mL~(-1),差异有统计学意义(P<0.05)。试验组有效率为82.35%(28/34例),对照组为58.82%(20/34例),差异有统计学意义(P<0.05)。治疗后2,4周,试验组的简易精神状态检查量表(MMSE)评分分别为(23.44±3.15),(27.41±3.48)分,对照组的MMSE分别为(20.35±2.35),(22.24±2.97)分,差异有统计学意义(P<0.01)。2组治疗过程中均没有出现明显的药物不良反应。结论神经节苷脂注射液可以有效降低重症颅脑损伤患者的血清NSE和S100B蛋白浓度。
Objective To observe the effect of ganglioside (Gg) injection on serum neuron specific enolase (NSE) and S100B protein concentration in patients with severe craniocerebral injury. Methods Sixty-eight patients with acute craniocerebral injury were randomly divided into control group (34 cases) and experimental group (34 cases). The control group were given compound mannitol injection, 200m L each time, twice a day, intravenous infusion; Naofukong 1.2 g, 3 times a day, orally; the experimental group in the control group on the basis of intravenous infusion of monosialin four Sugar ganglioside 100 mg once daily, 2 courses of treatment are 2 months. Fasting peripheral venous blood was collected on the 8th, 24th, 48th, 72th, and 120th hour after hospitalization, respectively. Serum NES and S100B protein levels were detected by enzyme-linked immunosorbent assay in 2 groups. The clinical efficacy was also evaluated in 2 groups. Group of adverse drug reactions occurred. Results Serum NSE of test group and control group were (13.21 ± 2.78) and (18.52 ± 3.45) ng · mL -1, respectively, and S100B were (2.08 ± 0.85) and (3.76 ± 2.14) ng · mL ~ (-1), the difference was statistically significant (P <0.05). The effective rate of the experimental group was 82.35% (28/34 cases) and that of the control group was 58.82% (20/34 cases), the difference was statistically significant (P <0.05). The scores of MMSE in the experimental group were (23.44 ± 3.15) and (27.41 ± 3.48) points respectively at 2 and 4 weeks after treatment, and those in the control group were (20.35 ± 2.35) and (22.24 ± 2.97) points, the difference was statistically significant (P <0.01). No significant adverse drug reactions occurred in the two groups during the course of treatment. Conclusion Ganglioside injection can effectively reduce serum NSE and S100B protein concentrations in patients with severe craniocerebral injury.